Giant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571 | Zendy

Teng-Wei Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Giant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571

Author(s) -

Teng-Wei Chen

Publication year - 2005

Publication title -

world journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.427

H-Index - 155

eISSN - 2219-2840

pISSN - 1007-9327

DOI - 10.3748/wjg.v11.i2.260

Subject(s) - medicine , imatinib mesylate , retrospective cohort study , survival rate , surgical margin , imatinib , gastroenterology , resection margin , stromal tumor , tyrosine kinase inhibitor , gist , log rank test , stromal cell , survival analysis , surgery , oncology , cancer , resection , myeloid leukemia

Malignant gastrointestinal stromal tumors (GISTs) are rare. Tumors larger than 10 cm tend to recur earlier: the larger the volume of the tumor, the worse the prognosis. We hypothesized that treatment with imatinib mesylate (Gleevec; STI-571), a c-kit tyrosine kinase inhibitor, as palliative therapy would prolong the survival of patients with recurrent giant malignant GISTs after resection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research